233 related articles for article (PubMed ID: 31426645)
1. The Pharmacoeconomic Analysis of Cetuximab and Panitumumab in the 1st Line Treatment of mCRC in Real Clinical Practice in the Czech Republic.
Sehnalová I; Říhová B; Němeček R; Kintrová K; Demlová R
Klin Onkol; 2019; 32(4):288-293. PubMed ID: 31426645
[TBL] [Abstract][Full Text] [Related]
2. [The cost study of first- line treatment of metastatic colorectal carcinoma with bevacizumab- containing regimen in the Czech Republic].
Hradecká I; Ríhová B; Horová R; Demlová R
Klin Onkol; 2014; 27(4):255-60. PubMed ID: 25115714
[TBL] [Abstract][Full Text] [Related]
3. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Shi Y; Wan X; Tan C; Li J; Peng L
Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
[TBL] [Abstract][Full Text] [Related]
4. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG
Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
[TBL] [Abstract][Full Text] [Related]
5. Tumour location and efficacy of first-line EGFR inhibitors in
Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
Gürsoy P; Çakar B; Almuradova E; Karateke M; Doğanavşargil B; Sezak M; Harman M; Karabulut B
J Chemother; 2021 May; 33(3):180-186. PubMed ID: 33349195
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review.
Koilakou S; Petrou P
Mol Diagn Ther; 2021 Nov; 25(6):715-734. PubMed ID: 34816395
[TBL] [Abstract][Full Text] [Related]
9. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
Pettigrew M; Kavan P; Surprenant L; Lim HJ
J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
[TBL] [Abstract][Full Text] [Related]
10. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
da Silva WC; de Araujo VE; Lima EMEA; Dos Santos JBR; Silva MRRD; Almeida PHRF; de Assis Acurcio F; Godman B; Kurdi A; Cherchiglia ML; Andrade EIG
BioDrugs; 2018 Dec; 32(6):585-606. PubMed ID: 30499082
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
Kratz JD; Uboha NV; Lubner SJ; Mulkerin DL; Clipson L; Yi Y; Yu M; Matkowskyj KA; LoConte NK; Deming DA
J Natl Compr Canc Netw; 2018 Dec; 16(12):1442-1450. PubMed ID: 30545991
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
Carvalho AC; Leal F; Sasse AD
PLoS One; 2017; 12(4):e0175409. PubMed ID: 28403233
[TBL] [Abstract][Full Text] [Related]
16. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Graham CN; Hechmati G; Fakih MG; Knox HN; Maglinte GA; Hjelmgren J; Barber B; Schwartzberg LS
J Med Econ; 2015; 18(8):619-28. PubMed ID: 25822327
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer--Czech Republic Model Adaptation].
Fínek J; Skoupá J; Jandová P
Klin Onkol; 2015; 28(4):265-72. PubMed ID: 26299740
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
20. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Köstek O; Demircan NC; Gökyer A; Küçükarda A; Sunal BS; Hacıoğlu MB; Eslame H; Solak S; Yılmaz E; Uzunoğlu S; Tunçbilek N; Çiçin I; Erdoğan B
Clin Transl Oncol; 2019 Nov; 21(11):1510-1517. PubMed ID: 30924091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]